Neoadjuvant Pembrolizumab Shows Potential Benefits in Early-Stage dMMR/MSI-High CRC
By Kai-Keen Shiu, MD, PhD - Last Updated: March 19, 2025Kai-Keen Shiu, MD, PhD, discusses his latest research investigating neoadjuvant pembrolizumab for patients with colorectal cancer.
Advertisement
Dr. Shiu also discusses how the NEOPRISM-CRC study exceeded its primary endpoint with a high pCR rate.
View his continued comments on TMD as a Prospective Biomarker for Patients With CRC.
Advertisement
Related Posts
The DYNAMIC study began in 2015 to analyze the efficacy of ctDNA in guiding the use of adjuvant chemotherapy.
Dr. Alan Venook reflects on how his leadership roles have shaped his collaborative approach to cancer research and treatment.
Sotorasib plus panitumumab may prolong progression-free survival in patients with KRAS G12C mCRC.
Experts speak on the new face of CRC, the potential mechanisms for these trends, and how CRC screening programs should react.
Dr. Tie discusses the beneficial results seen with a ctDNA-guided approach, and touches on its role in future trials.
630 Madison Ave.
Manalapan, NJ 07726
About Column
Contribute Column
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.